Sign In


A Farenax® pack contains:
i.  3 round Sulfadoxine + Pyrimethamine tablets each containing 500 mg Sulfadoxine and 25 mg Pyrimethamine.
ii. 3 oblong Artesunate tablets each containing 200 mg Artesunate base.

Properties, effects:
Farenax® exerts it’s antimalarial effect through the synergistic activity of all its components
(Sulfadoxine, Pyrimethamine and Artesunate). Sulfadoxine and Pyrimethamine acts by reciprocal potentiation of its two components, achieved by a sequential blockage of two enzymes involved in the biosynthesis of folic acid in parasites.

Artesunate has a rapid and potent schizonticidal activity against malaria parasites.  It has a peroxide bond which breaks up inside the parasite forming singlet oxygen (free radicals) which  exert a direct cytotoxic effect on the cells.  By virtue of this marked synergistic action, Farenax® is also effective against strains that are resistant to other commonly used antimalarial drugs, such as chloroquine and other 4-aminoquinoline derivatives, proguanil, Pyrimethamine and Sulfonamide-Pyrimethamine combinations.

Farenax® being an Artemisinin based Combination product, has a marked reduction of the likelihood of resistance development to the individual components.

Following oral administration, Farenax® is rapidly absorbed, peak plasma levels for Sulfadoxine is reached after about 16 hours, Pyrimethamine after 2 to 4 hours and Artesunate in 1 - 2 hours.

In humans, binding to plasma protein is 87.6% for Sulfadoxine, 92.5% for Pyrimethamine and 50% for Artesunate.
Elimination half - life is 200 hours for sulfadoxine, 100 hours for Pyrimethamine and approximately 2 to 4 hours for Artesunate.  Artesunate is metabolised in the liver by hydrolysis giving rise to dihydroartemisinin, which is also effective against malaria by the same mechanism of action.

Treatment of all forms of malaria due to Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.

Farenax® is contraindicated in patients who are hypersensitive to any of its active substances or to any of its excipients.
Fetal malformation has been observed in rats when Sulfadoxine + Pyrimethamine alone was administered in early pregnancy, this was due to Pyrimethamine, the folic acid antagonist.  Although Pyrimethamine is not known to cause fetal malformation in humans.  Farenax® should not be administered in the first trimester of pregnancy.

Dosage and administration:
Adult dose: (Above 12 years)
3 round  tablets of Sulfadoxine + Pyrimethamine and 1 oblong caplet of Artesunate to be taken at once on the first day, then 1 oblong caplet of Artesunate on the 2nd and 3rd day.